Calendario de vacunaciones de la Asociación Española de Pediatría (CAV-AEP): recomendaciones 2017

  1. David Moreno-Pérez
  2. Francisco José Álvarez García
  3. Javier Arístegui Fernández
  4. María José Cilleruelo Ortega
  5. José María Corretger Rauet
  6. Nuria García Sánchez
  7. Ángel Hernández Merino
  8. Teresa Hernández-Sampelayo Matos
  9. Manuel Merino Moína
  10. Luis Ortigosa del Castillo
  11. Jesús Ruiz-Contreras
Journal:
Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

ISSN: 1695-4033,  1696-4608

Year of publication: 2017

Volume: 86

Issue: 2

Pages: 98-98

Type: Article

DOI: 10.1016/J.ANPEDI.2016.10.009 PMID: 28038948 SCOPUS: 2-s2.0-85009270131 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

Abstract

The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV- AEP) annually publishes the immunisation schedule which, in our opinion, is considered optimal for children resident in Spain, taking into account the evidence available on current vaccines. Pneumococcal and varicella immunisation in early childhood is already included in all funded vaccines present in the regional immunisation programmes. Furthermore, this committee establishes recommendations on vaccines not included in official calendars (non-funded immunisations), such as rotavirus, meningococcal B, and meningococcal ACWY. As regards funded immunisations, 2+1 strategy (2, 4, 11-12 months) with hexavalent (DTaP-IPV-Hib-HB) and 13-valent pneumococcal vaccines is recommended. Administration of the 6-year booster dose with DTaP is recommended, as well as a poliomyelitis dose for children who had received the 2+1 scheme, with the Tdap vaccine for adolescents and pregnant women between 27 and 32 weeks gestation. The two-dose scheme should be used for MMR (12 months and 2-4 years) and varicella (15 months and 2-4 years). Coverage of human papillomavirus vaccination in girls aged 12 with a two-dose scheme (0, 6 months) should be improved. Information and recommendations for male adolescents about potential beneficial effects of the tetravalent HPV vaccine should also be provided. ACWY meningococcal vaccine is the optimal choice in adolescents. For recommended unfunded immunisations, the CAV-AEP recommends the administration of meningococcal B vaccine, due to the current availability in Spanish community pharmacies, with a 3+1 scheme. CAV-AEP requests the incorporation of this vaccine in the funded unified schedule. Vaccination against rotavirus is recommended in all infants.

Bibliographic References

  • 1 Consejo Interterritorial del Sistema Nacional de Salud. Calendario común de vacunación infantil. Calendario recomendado 2017. [consultado 30 Sept 2016]. Disponible en: http://www.msssi.gob.es/ciudadanos/proteccionSalud/vacunaciones/docs/CalendarioVacunacion2017.pdf.
  • 10 Public Health England (PHE). Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine. [consultado 30 Sept 2016]. Disponible en: https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-not-covered-by-prevenar-13-vaccine/pneumococcal-disease-infections-caused-by-serotypes-not-in-prevenar-13-vaccine.
  • 11 National Institute for Health Welfare, Finland. Incidence of invasive pneumococcal disease in Finland. [en línea]. [consultado 30 Sept 2016]. Disponible en: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland.
  • 12 Moreira, M., Cintra, O., Harriague, J., Hausdorff, W.P., Hoet, B., Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program. Vaccine. 34 (2016), 2766–2778.
  • 13 Guevara, M., Barricarte, A., Torroba, L., Herranz, M., Gil-Setas, A., Gil, F., et al. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: Cohort and case control study. Euro Surveill., 21, 2016 pii = 30186.
  • 14 Dirección General de Salud Pública. Servicio de Epidemiología. Enfermedad neumocócica invasora en la Comunidad de Madrid, año 2014 Sistema de vigilancia EDO. [consultado 30 Sept 2016]. Disponible en: http://www.madrid.org/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadervalue1=filename%3DMayo+2015.pdf&blobkey=id&blobtable=MungoBlobs&blobwhere=1352895623308&ssbinary=true.
  • 15 Dirección General de Salud Pública. Consellería de Sanitat Universal y Salut Pública. Generalitat Valenciana. Informe sobre la enfermedad neumocócica invasora. Comunitat Valenciana. Vigilancia epidemiológica 2015. [consultado 30 Sept 2016]. Disponible en: http://www.sp.san.gva.es/indexPortal.jsp?menuRaizPortal=SANMS50000&Portal=EPIDEMIOLOGIA&perfil=inst.
  • 16 Sigurdsson, S., Kristinsson, K.G., Erlendsdóttir, H., Hrafnkelsson, B., Haraldsson, A., Decreased incidence of respiratory infections in children after vaccination with ten-valent pneumococcal vaccine. Pediatr Infect Dis J. 34 (2015), 1385–1390.
  • 17 Greenberg, D., Givon-Lavi, N., Ben Shimol, S., Bar Ziv, J., Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children < 5 years. Vaccine. 33 (2015), 4623–4629.
  • 18 Ben-Shimol, S., Givon-Lavi, N., Leibovitz, E., Raiz, S., Greenberg, D., Dagan, R., Impact of widespread introduction of pneumoccal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 63 (2016), 611–618.
  • 19 Grupo de trabajo MenCC 2012. Ponencia de programa y registro de vacunaciones. Revisión del programa de vacunación frente a enfermedad meningocócica por serogrupo C. Enero de 2013. [consultado 30 Sept 2016]. Disponible en: http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/MenC.pdf.
  • 2 Centro Nacional de Epidemiología. Boletín Epidemiológico Semanal en Red. 26 de enero de 2016. [consultado 30 Sept 2016]. Disponible en: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-boletines/fd-boletin-epidemiologico-semanal-red/pdf_2016/IS-160126-WEB.pdf.
  • 20 Centro Nacional de Vigilancia Epidemiológica. Instituto de Salud Carlos III. Enfermedad meningocócica. Actualización temporada 2014-2015. [consultado 30 Sept 2016]. Disponible en: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-boletines/fd-boletin-epidemiologico-semanal-red/pdf_2015/IS-151013-WEB.pdf.
  • 21 Abad, R., Vázquez, J.A., Early evidence of expanding W ST11CC meningococcal incidence in Spain. J Infect. 73 (2016), 296–297.
  • 22 Fichas técnicas de vacunas. Página web del CAV-AEP. [consultado 30 Sept 2016]. Disponible en: http://vacunasaep.org/profesionales/fichas-tecnicas-vacunas.
  • 23 Public Health England (PHE). MenC vaccination schedule: planned changes from July 2016. [consultado 30 Sept 2016]. Disponible en: https://www.gov.uk/government/publications/menc-vaccination-schedule-planned-changes-from-july-2016.
  • 24 European Centre for Disease Prevention and Control (ECDC). Surveillance report. Measles and rubella monitoring. July 2016. [consultado 30 Sept 2016]. Disponible en: http://ecdc.europa.eu/en/publications/Publications/measles-rubella-monitoring-july-2016.pdf.
  • 25 AEPap. Calendarios de vacunación en España: todos en una tabla [consultado 30 Sept 2016]. Disponible en: http://www.aepap.org/vacunas/calendarios-espanoles.
  • 26 García-Cenoz, M., Castilla, J., Chamorro, J., Martínez-Baz, I., Martínez-Artola, V., Irisarri, F., et al. Impact of universal two dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012. Euro Surveill., 18, 2013 pii = 20552.
  • 27 Marin, M., Marti, M., Kambhampati, A., Jeram, S.M., Seward, J.F., Global varicella vaccine effectiveness: A meta-analysis. Pediatrics., 137, 2016, e20153741.
  • 28 European Centre for Disease Prevention and Control (ECDC). Varicella vaccination in the European Union. Stockholm: ECDC; 2015. [consultado 30 Sept 2016]. Disponible en: http://ecdc.europa.eu/en/publications/publications/varicella-guidance-2015.pdf.
  • 29 Lopez, A.S., Zhang, J., Marin, M., Epidemiology of varicella during the 2-dose varicella vaccination program–United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 65 (2016), 902–905.
  • 3 Dabrera, G., Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis. 60 (2015), 333–337.
  • 30 Garland, S.M., Kjaer, S.K., Muñoz, N., Block, S.L., Brown, D.R., DiNubile, M.J., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience. Clin Infect Dis. 63 (2016), 519–527.
  • 31 Angioli, R., Lopez, S., Aloisi, A., Terranova, C., De Cicco, C., Scaletta, G., et al. Ten years of HPV vaccines: State of art and controversies. Crit Rev Oncol Hematol. 102 (2016), 65–72.
  • 32 Willame, C., Rosillon, D., Zima, J., Angelo, M.G., Stuurman, A.L., Vroling, H., et al. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother., 2016, 1–10 [Epub ahead of print].
  • 33 Olsen, D., Gylling, A., Olsen, J., Richard, P., Drury, R., Early decrease in anogenital warts treatment when introducing a broad quadrivalent HPV vaccination program: A study from 3 nordic countries. EUROGIN, 2015 (Abstract p11-1).
  • 34 Pitisuttithum, P., Velicer, C., Luxembourg, A., 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines. 14 (2015), 1405–1419.
  • 35 Public Health England (PHE). Introduction of MenB immunisation for infants. Introduction from September 2015. 22th June 2015. [consultado 30 Sept 2016]. Disponible en: https://www.gov.uk/government/publications/menb-vaccination-introduction-from-1-september-2015.
  • 36 Public Health England (PHE). Vaccine cuts cases of meningitis and septicaemia in UK infants. 5th september 2016. [consultado 30 Sept 2016]. Disponible en: https://www.gov.uk/government/news/vaccine-cuts-cases-of-meningitis-and-septicaemia-in-uk-infants.
  • 37 Public Health England (PHE). National norovirus and rotavirus. Report Summary of surveillance of norovirus and rotavirus 7th September 2016–reporting weeks 31-34. [consultado 30 Sept 2016]. Disponible en: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/551030/Norovirus_update_2016_weeks_31_34.pdf.
  • 38 Cortese, M., Dahl, R., Cums, A., Parashar, U., Protection against gastroenteritis in US households with children who received rotavirus vaccine. J Infect Dis. 211 (2015), 558–562.
  • 39 Rivero-Calle, I., Gómez-Rial, J., Martinón-Torres, F., Systemic features of rotavirus infection. J Infect. 72 (2016), S98–S105.
  • 4 Eberhardt, C.S., Blanchard-Rohner, G., Lemaître, B., Boukrid, M., Combescure, C., Othenin-Girard, V., et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis. 62 (2016), 829–836.
  • 40 Rosillon, D., Buyse, H., Friedland, L.R., Ng, S.P., Velázquez, F.R., Breuer, T., Risk of intussusception after rotavirus vaccination. Meta-analysis of postlicensure studies. Pediatr Infect Dis J. 34 (2015), 763–768.
  • 5 Public Health England (PHE). Vaccine update: issue 242, March 2016. Ref: PHE Publications Gateway Number: 2015738. Pertussis vaccination in pregnancy–change to guidance from 1 April 2016. [consultado 30 Sept 2016]. Disponible en: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/510376/PHE_9750_VU_242_March_2016_03_web.pdf.
  • 6 Klein, N.P., Bartlett, J., Fireman, B., Baxter, R., Waning Tdap effectiveness in adolescents. Pediatrics. 137 (2016), 1–9.
  • 7 Moore, M.R., Link-Gelles, R., Schaffner, W., Lynfield, R., Holtzman, C., Harrison, L.H., et al. Effectiveness of 13-valent pneumococcal conjugate vaccines for prevention of invasive pneunmococcal disease in children in the USA: A matched case-control study. Lancet Respir Med. 4 (2016), 399–406.
  • 8 Deceuninck, G., de Serres, G., Boulianne, N., Lefevre, B., de Wals, P., Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 34 (2016), 2053–2054.
  • 9 Moore, M.R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennet, N.M., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children and adults in the USA: Analysis of multisite, population-based surveillance. Lancet Infect Dis. 15 (2015), 301–309.
Data source: Dialnet